AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02462473
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Trial: NCT02462473
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
Trial: NCT02871297
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Trial: NCT02840097
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.
Trial: NCT00164775
Drug: Imipramine
RxNorm normalized name: Imipramine
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
Trial: NCT04397107
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were received low dose recombinant human Interleukin-2
Trial: NCT03754309
Drug: KY1005
RxNorm normalized name: Immunoglobulin g4 (235-proline,242-glutamic acid), anti-(human ox40 ligand) (human monoclonal ky1005-2d10 .gamma.4-chain), disulfide with human monoclonal ky1005-2d10 .kappa.-chain, dimer
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A human anti-OX40 ligand monoclonal antibody
Trial: NCT00784966
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
Trial: NCT00784966
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
Trial: NCT00136591
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
Trial: NCT00136591
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
Trial: NCT02014064
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)
Trial: NCT00666627
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate 35mg once weekly
Trial: NCT00666627
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70mg once weekly
Trial: NCT01409499
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib monotherapy, 400mg Bid, continuously
Trial: NCT02225405
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02225405
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02225405
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00703664
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.
Trial: NCT00703664
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
Trial: NCT01637233
Drug: Arm 2 Maraviroc and Protease Inhibitors
RxNorm normalized name: Protease inhibitors
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc + PI
Trial: NCT01637233
Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc + NRTI
Trial: NCT01147939
Drug: Elacytarabine
RxNorm normalized name: Elacytarabine
DrugBank: Elacytarabine (DB05494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Trial: NCT00030810
Drug: Taxotere/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere/Cisplatin
Trial: NCT00797823
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
Trial: NCT00953758
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
Trial: NCT00810979
Drug: SLx-4090
RxNorm normalized name: SLx-4090
DrugBank: SLx-4090 (DB05678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00003211
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003211
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003211
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02956525
Drug: Dexibuprofen
RxNorm normalized name: Dexibuprofen
DrugBank: Dexibuprofen (DB09213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen 200 mg
Trial: NCT00302250
Drug: ALT-711 (alagebrium chloride)
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02702648
Drug: AC-082
RxNorm normalized name: Ac
DrugBank: Actinium (DB12860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules for oral administration
Trial: NCT01882491
Drug: gevokizumab
RxNorm normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00999908
Drug: Indacaterol 150 μg
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Trial: NCT00999908
Drug: Tiotropium 18 μg
RxNorm normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Trial: NCT01608360
Drug: Intravenous lidocaine injection
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
Trial: NCT04302532
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antioxidant used to decrease oxidative stress and improve fertility prospects
Trial: NCT04302532
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ovulation induction drug
Trial: NCT04420598
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowe
Trial: NCT01608360
Drug: Intravenous normal saline injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Trial: NCT03359863
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
Trial: NCT02349763
Drug: Intravenous Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
Trial: NCT02349763
Drug: Oral Dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
Trial: NCT01181414
Drug: Beta blocker/digoxine/amiodarone
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ventricular rate control by using drug treatment.
Trial: NCT01945450
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00009971
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01511770
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole Tablets, 200 mg
Trial: NCT01511770
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg tablets
Trial: NCT02541227
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
Trial: NCT04185857
Drug: canrenone 50-100 mg orally once a day
RxNorm normalized name: canrenone
DrugBank: Canrenone (DB12221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
Trial: NCT04185857
Drug: olmesartan 10-20 mg orally once a day
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone.
Trial: NCT00993031
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LPV 200mg/r 50mg
Trial: NCT00993031
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600mg
Trial: NCT00993031
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 300 mg
Trial: NCT00993031
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine 150 mg
Trial: NCT00634829
Drug: albuterol (Armstrong Albuterol HFA)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
Trial: NCT00634829
Drug: Albuterol Sulfate (Provenetil-HFA)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
Trial: NCT00465595
Drug: psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of psilocybin received in the two sessions will range anywhere from low to high.
Trial: NCT00005059
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01937182
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram 10-40 mg per day administered orally
Trial: NCT00005059
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04600895
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir
Trial: NCT00309569
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubucin 60mg/m2 (only node-positive patients)
Trial: NCT01310621
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)
Trial: NCT01834729
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
Trial: NCT02762474
Drug: nab-paclitaxel group
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
Trial: NCT01747174
Drug: IC Sodium nitroprusside (SNP)
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
Trial: NCT00288080
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Premedication of dexamethasone prior to docetaxel, per institutional standards.
Trial: NCT00288080
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
Trial: NCT00288080
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
Trial: NCT01223001
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Trial: NCT01223001
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Trial: NCT00786682
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00786682
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00107471
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01441570
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will take nebivolol daily for 12 weeks.
Trial: NCT01441570
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will take metoprolol succinate daily for 12 weeks.
Trial: NCT01127165
Drug: zonisamide low dose group
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.
Trial: NCT01127165
Drug: zonisamide high dose group
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
Trial: NCT00379795
Drug: Ranibizumab 0.5 mg
RxNorm normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
Trial: NCT01244880
Drug: PF-02545920
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-02545920 10 mg single dose
Trial: NCT03302039
Drug: Single shot phenylephrine
RxNorm normalized name: ChoreMate One-Shot
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
Trial: NCT03302039
Drug: Fixed infusion phenylephrine.
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
Trial: NCT03302039
Drug: Variable infusion phenylephrine.
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
Trial: NCT03302039
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
Trial: NCT01244880
Drug: PF-02545920
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-02545920 10 mg tablet single dose
Trial: NCT02933658
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02933658
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00031161
Drug: Nitisinone (NTBC)
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00031161
Drug: Dichloroacetate
RxNorm normalized name: Dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: no
EMA approved: no
PMDA approved: no